• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » iCad inks $7m private placement deal

iCad inks $7m private placement deal

December 28, 2018 By Sarah Faulkner

iCadiCad (NSDQ:ICAD) said this week that it landed a $7 million private placement deal with institutional investors.

The company will pay interest to the investors on the outstanding principal amount at an annual rate of 5%, according to a report filed with the SEC. The convertible debentures mature on Dec. 21, 2021.

Prior to the maturity date, the convertible debentures can be converted into shares of common stock at $4.00 per share, iCad added.

The private placement, which closed earlier this month, resulted in net proceeds of roughly $6.5 million. The company said it plans to use the money for general corporate purposes.

In the same SEC report, iCad said that the company’s EVP & CFO Richard Christopher resigned to pursue “another professional opportunity.” The company named R. Scott Areglado, iCad’s corporate controller, as interim CFO.

Earlier this year, iCad re-jiggered its board of directors, naming a new chairman and reorganizing its oversight committees, after a member filed his resignation.

Longtime shareholder Andy Sassine tendered his resignation in September, writing that he could “no longer stand idly by while the Board’s inaction and misdirection directly harms the interests of iCad’s shareholders.”

Filed Under: Business/Financial News, Featured, Funding Roundup, Oncology, Wall Street Beat Tagged With: iCad Inc.

More recent news

  • J&J launches faster Shockwave coronary catheter in the US
  • Abbott’s Cologuard Plus screening test receives CE Mark
  • Haemonetics wins FDA approval of PerQseal Elite vascular closure system
  • Medtronic announces a company president
  • Medtronic nets CE mark for Vitalis family of conduction system pacemakers

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy